Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158
Recruiting
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Urothelial Carcinoma, Bladder Cancer
Register for Updates
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
NCT01851694
Recruiting
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has man... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cystic Fibrosis, Pancreatic Insufficiency
Register for Updates
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
NCT01838512
Recruiting
The purpose of this study is to assess the clinical effectiveness of all approved multiple myeloma (MM) therapies in the newly-diagnosed (NDMM) and the relapsed/refractory MM (RRMM) settings in real-world clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institute, Pottstown, Pennsylvania
Conditions: Multiple Myeloma
Register for Updates
Digital Incentive Spirometry Adherence
NCT06629454
Recruiting
This single-arm proof-of-concept research study aims to assess the effect of a digital incentive spirometer (IS) device and a companion mobile-based app on incentive spirometry adherence in patients post-surgery. The digital IS utilizes a sensor to measure inspiratory breaths, and these data are transmitted wirelessly to a secure cloud database. The spirometer and app include a patient reminder system, exercise gamification strategies, progress tracking, and additional features designed to promo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Penn Medicine Valley Forge, Berwyn, Pennsylvania
Conditions: Pulmonary Function, Incentive Spirometry, Patient Adherence, Lung Resection, Thoracic Surgery
Register for Updates
Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)
NCT06499896
Recruiting
Multiple retrospective studies suggest that the administration of corticosteroids to treat irAEs is safe, and does not compromise efficacy of ICI therapy in cancer patients. While \~67% of patients respond to corticosteroids, 33% of patients require biologic therapy such as TNFα inhibitors (e.g. infliximab), integrin α4β7 inhibitors (e.g. vedolizumab), or JAK/STAT inhibitors (e.g. tofactinib). This study aims to determine that distinct pathobionts govern the development of irCAE and IMC; and tha... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Immune-mediated Colitis (IMC), Immune-related Dermatitis
Register for Updates
Cryoablation for Monomorphic Ventricular Tachycardia
NCT05675865
Recruiting
The objective of this clinical study is to evaluate the safety and effectiveness of the Adagio VT Cryoablation System in the ablation treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Hospital of University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Sustained VT
Register for Updates
Fecal Microbiota Transplant National Registry
NCT03325855
Recruiting
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: Temple University, Philadelphia, Pennsylvania
Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Register for Updates
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
NCT06482853
Recruiting
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/24/2025
Locations: Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Obesity, Hypertension
Register for Updates
Bright Light Therapy for OSA
NCT05917119
Recruiting
Persistent daytime symptoms of sleepiness in individuals with obstructive sleep apnea (OSA) who are using Continuous Positive Airway Pressure (CPAP) are associated with adverse long term medical and functional outcomes. Supplementary exposure to bright light has beneficial effects on sleep quality and daytime vigilance in healthy individuals and it has been increasingly applied in a variety of sleep and neuropsychiatric conditions. This study will explore the role of Bright Light Therapy (BLT),... Read More
Gender:
ALL
Ages:
Between 40 years and 65 years
Trial Updated:
01/24/2025
Locations: VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania
Conditions: Obstructive Sleep Apnea
Register for Updates
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT05655312
Recruiting
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination with Nivolumab in subjects with unresectable and metastatic melanoma.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/23/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Mucosal Melanoma, Melanoma Stage III
Register for Updates
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
NCT05271578
Recruiting
To examine vascular reactivity and inflammatory biomarkers via quantitative magnetic resonance imaging (MRI) and blood serum, respectively, in a crossover study where active vapers (electronic cigarette users) and smokers will undergo three separate acute exposure-episodes of electronic cigarette +/- nicotine and tobacco-cig. The MRI exams and blood draws will be performed pre- and post-exposure. The results will be compared against baseline values derived from a group of non-smokers/non-vapers,... Read More
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
01/23/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Vascular Reactivity, Serum Biomarkers
Register for Updates
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
NCT04680468
Recruiting
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous stem cell transplant consolidation and mainten... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/23/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Myeloma
Register for Updates